Luoxin Pharmaceuticals Group Stock Co., Ltd.
SZSE:002793.SZ
5.28 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,342.619 | 3,587.547 | 6,477.933 | 6,095.946 | 7,588.791 | 935.446 | 828.044 | 637.397 | 584.212 | 537.326 | 474.174 | 474.637 | 423.43 |
| Cost of Revenue
| 1,378.039 | 2,628.209 | 3,226.631 | 2,826.132 | 2,799.713 | 692.622 | 575.822 | 454.127 | 414.149 | 388.296 | 360.841 | 364.238 | 336.471 |
| Gross Profit
| 964.58 | 959.338 | 3,251.301 | 3,269.813 | 4,789.078 | 242.824 | 252.222 | 183.27 | 170.063 | 149.03 | 113.333 | 110.399 | 86.958 |
| Gross Profit Ratio
| 0.412 | 0.267 | 0.502 | 0.536 | 0.631 | 0.26 | 0.305 | 0.288 | 0.291 | 0.277 | 0.239 | 0.233 | 0.205 |
| Reseach & Development Expenses
| 81.097 | 204.725 | 320.946 | 361.268 | 419.995 | 33.354 | 30.948 | 24.295 | 22.303 | 21.565 | 16.39 | 78.061 | 0 |
| General & Administrative Expenses
| 138.708 | 124.701 | 96.644 | 101.92 | 94.753 | 12.581 | 15.562 | 10.861 | 9.716 | 9.348 | 7.487 | 33.786 | 29.469 |
| Selling & Marketing Expenses
| 964.013 | 1,729.958 | 1,866.371 | 2,002.538 | 3,247.975 | 26.662 | 20.929 | 18.242 | 15.918 | 13.855 | 9.705 | 10.414 | 7.815 |
| SG&A
| 1,315.877 | 1,854.659 | 1,963.015 | 2,104.458 | 3,342.728 | 39.243 | 36.491 | 29.103 | 25.635 | 23.203 | 17.193 | 44.2 | 37.284 |
| Other Expenses
| -57.757 | 312.722 | 285.592 | 252.242 | 220.71 | -0.242 | -0.099 | 2.572 | 3.626 | 4.024 | 1.028 | 0.262 | -0.241 |
| Operating Expenses
| 1,454.731 | 2,372.106 | 2,569.553 | 2,717.968 | 3,983.434 | 114.448 | 106.115 | 83.008 | 71.353 | 64.116 | 49.507 | 46.451 | 39.042 |
| Operating Income
| -490.151 | -1,412.768 | 698.959 | 425.737 | 725.063 | 127.705 | 133.66 | 113.847 | 90.977 | 70.152 | 52.127 | 62.566 | 41.658 |
| Operating Income Ratio
| -0.209 | -0.394 | 0.108 | 0.07 | 0.096 | 0.137 | 0.161 | 0.179 | 0.156 | 0.131 | 0.11 | 0.132 | 0.098 |
| Total Other Income Expenses Net
| -129.816 | -50.172 | -213.758 | -16.805 | -0.853 | -0.913 | -12.545 | 15.87 | -4.111 | -10.745 | -10.793 | -1.12 | -6.687 |
| Income Before Tax
| -619.967 | -1,462.94 | 485.201 | 408.932 | 724.21 | 127.463 | 133.561 | 116.132 | 94.598 | 74.168 | 53.033 | 62.828 | 41.23 |
| Income Before Tax Ratio
| -0.265 | -0.408 | 0.075 | 0.067 | 0.095 | 0.136 | 0.161 | 0.182 | 0.162 | 0.138 | 0.112 | 0.132 | 0.097 |
| Income Tax Expense
| 164.806 | -204.954 | 63.555 | 66.33 | 70.455 | 16.117 | 17.71 | 15.769 | 12.811 | 10.209 | 7.069 | 9.162 | 8.709 |
| Net Income
| -661.138 | -1,257.986 | 406.096 | 320.701 | 633.95 | 111.346 | 115.852 | 100.363 | 81.787 | 63.959 | 45.964 | 53.666 | 32.521 |
| Net Income Ratio
| -0.282 | -0.351 | 0.063 | 0.053 | 0.084 | 0.119 | 0.14 | 0.157 | 0.14 | 0.119 | 0.097 | 0.113 | 0.077 |
| EPS
| -0.61 | -0.88 | 0.28 | 0.22 | 1.76 | 0.1 | 0.34 | 0.32 | 0.32 | 0.25 | 0.18 | 0.21 | 0.17 |
| EPS Diluted
| -0.61 | -0.88 | 0.28 | 0.22 | 0.57 | 0.1 | 0.34 | 0.32 | 0.32 | 0.25 | 0.18 | 0.21 | 0.17 |
| EBITDA
| -267.609 | -1,020.167 | 898.736 | 718.028 | 973.642 | 166.392 | 159.045 | 133.711 | 117.929 | 100.864 | 70.658 | 64.119 | 49.116 |
| EBITDA Ratio
| -0.114 | -0.284 | 0.139 | 0.118 | 0.128 | 0.178 | 0.192 | 0.21 | 0.202 | 0.188 | 0.149 | 0.135 | 0.116 |